HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens

SIMPLE SUMMARY: Neoadjuvant chemotherapy strategy (NAC) is a standard of care for Human Epidermal Growth Factor Receptor-2 (HER2)-positive early breast cancer but there is no proven beneficial evidence in terms of survival compared to the adjuvant chemotherapy strategy. Our retrospective study found...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancers (Basel)
Prif Awduron: Laas, Enora, Bresset, Arnaud, Féron, Jean-Guillaume, Le Gal, Claire, Darrigues, Lauren, Coussy, Florence, Grandal, Beatriz, Laot, Lucie, Pierga, Jean-Yves, Reyal, Fabien, Hamy, Anne-Sophie
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI 2021
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7864202/
https://ncbi.nlm.nih.gov/pubmed/33498405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13030370
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg